Pharma 2020 : the vision - which path will you take? : pharmaceutical practitioner

In June 2007, PriceWaterhouse- Coopers (PwC) released "Pharma 2020: The Vision - Which path will you take?", a report on the future of the pharmaceutical industry. It contends that despite unprecedented global demand for its product, particularly from fast-growing emerging markets like China and India, the pharmaceutical industry is at a pivotal point in its evolution.

[1]  M. Ivimey.  Annual report , 1958, IRE Transactions on Engineering Writing and Speech.

[2]  Nina Bawden,et al.  On the Run , 1964 .

[3]  Carol A. McCarthy,et al.  Influenza vaccines , 1965, The Medical letter on drugs and therapeutics.

[4]  C. H. B. Grant,et al.  Recapturing the Vision. , 1989 .

[5]  David L. Weitzman.  On the run , 2003, Nature.

[6]  T. Land.  Combating counterfeit drugs , 1992, Nature.

[7]  Amy M. Hightower,et al.  Science and Engineering Indicators , 1993 .

[8]  A. Kapur,et al.  The economic burden of diabetes in India: Results from a national survey , 2000 .

[9]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[10]  J. Iglehart,et al.  Centers for Medicare and Medicaid Services , 2020, Definitions.

[11]  D. Weston.  The Problem of Antimicrobial Resistance , 2001 .

[12]  D. Yach,et al.  Life Course Perspectives on Coronary Heart Disease, Stroke and Diabetes: Key issues and implications for policy and research , 2002 .

[13]  Paul Smaglik.  An industrial revolution , 2002, Nature.

[14]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[15]  W. Manning,et al.  Covering the uninsured: what is it worth? , 2004, Health affairs.

[16]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[17]  Joshua P Cohen,et al.  Switching prescription drugs to over the counter , 2004, BMJ : British Medical Journal.

[18]  Evelyne Lerut,et al.  Prospective Study on Late Consequences of Subclinical Non‐Compliance with Immunosuppressive Therapy in Renal Transplant Patients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  Nicholas Davies,et al.  Drugs, devices, and the promise of pervasive computing , 2004 .

[20]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[21]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[22]  J. Ioannidis.  Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.

[23]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[24]  Alastair Gray,et al.  Economic burden of cardiovascular diseases in the enlarged European Union. , 2006, European heart journal.

[25]  P. Webster.  US big businesses struggle to cope with health-care costs , 2006, The Lancet.

[26]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[27]  Stephen Emmott,et al.  Towards 2020 Science , 2006 .

[28]  Louise Atkins,et al.  Intentional and non-intentional non-adherence to medication amongst breast cancer patients. , 2005, European journal of cancer.

[29]  Housing Lin,et al.  Department of Health White Paper - Our health our care our say: a new direction for community services , 2007 .

[30]  J. Collier.  The Pharmaceutical Price Regulation Scheme , 2007, BMJ : British Medical Journal.

[31]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[32]  Corinne Le Quéré,et al.  Climate Change 2013: The Physical Science Basis , 2013 .